Full Press Release Details
NLS Pharmaceutics Announces the Submission of Three Research Abstracts
to the 2025 ASCP Annual Meeting
Zurich, Switzerland - January
30, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"),
a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders,
is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical
Psychopharmacology (ASCP).
The ASCP Annual Meeting, taking place from May 27 to May 30,
2025, at the Fairmont Scottsdale Princess in Scottsdale, Arizona, is one of the world's leading conferences dedicated to advancing
research in neuropsychopharmacology. This prestigious event provides a platform for cutting-edge research and innovative therapeutic approaches
in neuropsychiatric drug development, precision psychiatry, and addiction medicine.
NLS Submitted Research Abstracts:
Advancing Clinical Research in Neuropsychopharmacology
Pharmaceutics is honored to contribute to the 2025 ASCP Annual Meeting, one of the premier global platforms for advancing
clinical research in neuropsychopharmacology," said Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics.
"Our research spans innovative therapeutic solutions such as Mazindol ER for fentanyl dependence, dual orexin receptor agonists
for narcolepsy, and a multitarget approach to managing diabetes-related neurological and sleep disorders. These abstracts reflect our
commitment to addressing critical unmet medical needs in addiction medicine, sleep disorders, and cognitive health."
About NLS Pharmaceutics Ltd.
Ltd. is a Swiss-based clinical-stage biopharmaceutical company dedicated to the development of groundbreaking therapies for
rare and complex CNS disorders. The Company collaborates with world-renowned scientists and pharmaceutical partners to advance innovative
treatments in areas such as addiction medicine, sleep disorders, and cognitive dysfunction. For more information, visit www.nlspharma.com.
Forward-Looking Statements
contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking
statements when it discusses the potential of Mazindol ER and the AEX-41 and AEX-2 compounds for the treatment of various conditions.
These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject
to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking
statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing
its clinical trials; NLS products may not be approved by regulatory agencies, NLS technology may not be validated as it progresses further
and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge
is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may
wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical
settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS patents may not be sufficient;
NLS products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies,
products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual
results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required
by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties
affecting NLS is contained under the heading "Risk Factors" in NLS annual report on Form 20-F for the year ended December 31,
2023 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent
filings made by NLS with the SEC.
Investor Relations Contact